Tashi, T., Elberink, H. O., Akin, C., Castells, M., Panse, J., Radia, D., Siebenhaar, F., Livideanu, C. B., Hartmann, K., Broesby-Olsen, S., George, T., Sabato, V., Daele, P. V., Cerquozzi, S., Dybedal, I., Jurcic, J., Barete, S., Reiter, A., Pongdee, T., Desai, R., Schafhausen, P., Ustun, C., Bose, P., Vadas, P., Triggiani, M., Bonadonna, P., Deangelo, D., Rein, L., Vachhani, P., Bidollari, I., Lin, H., Hong, J., Lampson, B., Doyle, A., Álvarez-Twose, I., Gotlib, J. (2025). Avapritinib achieves deep and durable symptom control with a well-tolerated safety profile in ism: Long-term outcomes from pioneer. Blood. https://doi.org/10.1182/blood-2025-2024